IGLV2-23: A Potential Drug Target for Reproductive Medicine (G28813)

Target Name: IGLV2-23

NCBI ID: G28813

IGLV2-23

Other Name(s): V1-7 | Immunoglobulin lambda variable 2-23 | immunoglobulin lambda variable 2-23 | IGLV223

IGLV2-23: A Potential Drug Target for Reproductive Medicine

IGLV2-23 (V1-7) is a protein that is expressed in the human placenta and has been identified as a potential drug target in the field of reproductive medicine. The protein is a member of the IGLV2 family, which is known for its role in the development and maintenance of tissue repair and regeneration.

IGLV2-23 is expressed in the placenta, which is a vital organ that plays a critical role in the development and nourishment of fetuses. During fetal development, the placenta is responsible for providing the necessary nutrients and oxygen to the developing fetus, as well as removing waste products from the body.

IGLV2-23 has been shown to play a key role in the regulation of cellular processes that are important for placenta function. For example, studies have shown that IGLV2-23 can help to maintain the structural integrity of the placenta by preventing the breakdown of cell membranes. This is important for the placenta to function properly and support the development of the fetus.

In addition to its role in placenta function, IGLV2-23 has also been shown to be involved in a number of other cellular processes that are important for tissue repair and regeneration. For example, studies have shown that IGLV2-23 can help to promote the growth and proliferation of certain types of cells, as well as regulate the expression of genes that are involved in cell division and differentiation.

This suggests that IGLV2-23 could be a useful drug target for therapies that are aimed at repairing or regenerating damaged tissue. For example, IGLV2-23 could potentially be used to treat a variety of conditions that involve tissue damage or repair, such as trauma, burns, or diseases that affect theplacenta.

In conclusion, IGLV2-23 is a protein that has been identified as a potential drug target in the field of reproductive medicine. Its role in the regulation of cellular processes that are important for placenta function and tissue repair and regeneration makes it an attractive target for therapies that are aimed at these goals. Further research is needed to fully understand the potential implications of IGLV2-23 as a drug target, and to determine the most effective ways to use it for therapeutic purposes.

Protein Name: Immunoglobulin Lambda Variable 2-23

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268)

The "IGLV2-23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLV2-23 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets